Subvisible particle testing addresses regulatory limits for particulate matter in parenteral drugs, ophthalmic solutions, and lipid emulsions.

A revised version of the USP chapter on Subvisible Particulate Matter USP<1788> became official on 1 st May 2021. USP<1788> is meant to expand on the information given in the chapters <787>, <788> and ...

Subvisible particles have the potential to impact efficacy, safety, and regulatory compliance throughout the field of biotherapeutics. Conventional particle analysis methods only provide particle ...

Biotherapeutics continue to revolutionize how clinicians treat many human diseases. Protein therapies using molecules like peptides and monoclonal antibodies have become well established in the clinic ...

Subvisible particulate testing is critical to assess the safety of medical devices, and particulate contamination should be minimized to avoid possible negative health consequences to the patient. A ...

Halo Labs is an innovator in drug product characterization and subvisible particle analysis providing unprecedented product quality insights to improve patient safety. Starting with the launch of its ...